DK1530636T3 - Behandling af melanomer ved reduktion af clusterinniveauet - Google Patents
Behandling af melanomer ved reduktion af clusterinniveauetInfo
- Publication number
- DK1530636T3 DK1530636T3 DK03792074.1T DK03792074T DK1530636T3 DK 1530636 T3 DK1530636 T3 DK 1530636T3 DK 03792074 T DK03792074 T DK 03792074T DK 1530636 T3 DK1530636 T3 DK 1530636T3
- Authority
- DK
- Denmark
- Prior art keywords
- clusterin
- subject
- bcl
- treatment
- effective amount
- Prior art date
Links
- 102000003780 Clusterin Human genes 0.000 title abstract 7
- 108090000197 Clusterin Proteins 0.000 title abstract 7
- 201000001441 melanoma Diseases 0.000 title abstract 4
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 108091007065 BIRCs Proteins 0.000 abstract 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40519302P | 2002-08-21 | 2002-08-21 | |
| US40815202P | 2002-09-03 | 2002-09-03 | |
| US31974802P | 2002-12-02 | 2002-12-02 | |
| US47238703P | 2003-05-20 | 2003-05-20 | |
| PCT/CA2003/001276 WO2004018675A1 (en) | 2002-08-21 | 2003-08-21 | Treatment of melanoma by reduction in clusterin levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1530636T3 true DK1530636T3 (da) | 2010-11-29 |
Family
ID=31950766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03792074.1T DK1530636T3 (da) | 2002-08-21 | 2003-08-21 | Behandling af melanomer ved reduktion af clusterinniveauet |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7285541B2 (https=) |
| EP (1) | EP1530636B1 (https=) |
| JP (1) | JP4620585B2 (https=) |
| KR (1) | KR101052289B1 (https=) |
| AT (1) | ATE478142T1 (https=) |
| AU (1) | AU2003258425B2 (https=) |
| CA (1) | CA2494764C (https=) |
| CY (1) | CY1110936T1 (https=) |
| DE (1) | DE60333839D1 (https=) |
| DK (1) | DK1530636T3 (https=) |
| IL (1) | IL166657A (https=) |
| NO (1) | NO333254B1 (https=) |
| NZ (1) | NZ538288A (https=) |
| PT (1) | PT1530636E (https=) |
| SI (1) | SI1530636T1 (https=) |
| WO (1) | WO2004018675A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4785252B2 (ja) | 1999-02-26 | 2011-10-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｔｒｐｍ−２アンチセンス療法 |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| WO2003062421A1 (en) | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| SI1530636T1 (sl) | 2002-08-21 | 2010-12-31 | Stry Liaison Ofiice The University Of British Columbia Umiversity Indu | Zdravljenje melanoma z zniĹľanjem nivojev klusterina |
| KR101238701B1 (ko) | 2002-08-21 | 2013-03-05 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
| US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| BRPI0508970A (pt) * | 2004-03-19 | 2007-08-21 | Penn State Res Found | método combinatórios e composições para o tratamento de melanoma |
| US8710020B2 (en) | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| WO2006035432A2 (en) * | 2004-09-27 | 2006-04-06 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Gene silencing for use in dermatology |
| CA2584646C (en) * | 2004-11-23 | 2015-11-03 | The University Of British Columbia | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
| ES2543341T3 (es) | 2005-09-13 | 2015-08-18 | National Research Council Of Canada | Métodos y composiciones para modular la actividad de células tumorales |
| KR20080065617A (ko) * | 2005-09-19 | 2008-07-14 | 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 | 글루코코티코이드 수용체 발현의 조절 |
| AU2008293138A1 (en) * | 2007-08-28 | 2009-03-05 | Auckland Uniservices Limited | Cell marker of melanocyte cell lineage and uses thereof |
| EA034462B1 (ru) | 2009-11-24 | 2020-02-11 | Алетиа Байотерапьютикс Инк. | Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований |
| SG192957A1 (en) | 2011-03-15 | 2013-09-30 | Univ British Columbia | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
| AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
| US9822170B2 (en) | 2012-02-22 | 2017-11-21 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer |
| WO2014138338A1 (en) | 2013-03-06 | 2014-09-12 | The General Hospital Corporation | Combinatorial compositions and methods for treatment of melanoma |
| WO2014159775A1 (en) * | 2013-03-14 | 2014-10-02 | Teva Pharmaceutical Industries Ltd. | Anti-clusterin monotherapy for cancer treatment |
| US20230243852A1 (en) * | 2022-01-26 | 2023-08-03 | Idexx Laboratories, Inc. | Methods and compositions for differentiating progressive chronic kidney disease from stable chronic kidney disease |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6111094A (en) * | 1990-08-14 | 2000-08-29 | Isis Pharmaceuticals Inc. | Enhanced antisense modulation of ICAM-1 |
| US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| US5417978A (en) | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| AUPM672594A0 (en) * | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
| US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| AU760549B2 (en) * | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| WO2000034469A1 (en) | 1998-12-11 | 2000-06-15 | The Research Foundation Of State University Of New York At Albany | Compositions and methods for altering cell migration |
| JP4785252B2 (ja) * | 1999-02-26 | 2011-10-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｔｒｐｍ−２アンチセンス療法 |
| US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| CA2393646A1 (en) | 1999-12-21 | 2001-06-28 | Yale University | Survivin promotion of angiogenesis |
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| WO2003062421A1 (en) * | 2002-01-17 | 2003-07-31 | The University Of British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| KR101238701B1 (ko) * | 2002-08-21 | 2013-03-05 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
| SI1530636T1 (sl) | 2002-08-21 | 2010-12-31 | Stry Liaison Ofiice The University Of British Columbia Umiversity Indu | Zdravljenje melanoma z zniĹľanjem nivojev klusterina |
| US20040220131A1 (en) * | 2003-04-18 | 2004-11-04 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| US8061408B2 (en) | 2009-10-13 | 2011-11-22 | Varel Europe S.A.S. | Casting method for matrix drill bits and reamers |
-
2003
- 2003-08-21 SI SI200331891T patent/SI1530636T1/sl unknown
- 2003-08-21 DE DE60333839T patent/DE60333839D1/de not_active Expired - Lifetime
- 2003-08-21 JP JP2005501197A patent/JP4620585B2/ja not_active Expired - Fee Related
- 2003-08-21 NZ NZ538288A patent/NZ538288A/en not_active IP Right Cessation
- 2003-08-21 WO PCT/CA2003/001276 patent/WO2004018675A1/en not_active Ceased
- 2003-08-21 CA CA2494764A patent/CA2494764C/en not_active Expired - Fee Related
- 2003-08-21 AU AU2003258425A patent/AU2003258425B2/en not_active Ceased
- 2003-08-21 KR KR1020057002964A patent/KR101052289B1/ko not_active Expired - Fee Related
- 2003-08-21 US US10/646,391 patent/US7285541B2/en not_active Expired - Fee Related
- 2003-08-21 DK DK03792074.1T patent/DK1530636T3/da active
- 2003-08-21 PT PT03792074T patent/PT1530636E/pt unknown
- 2003-08-21 EP EP03792074A patent/EP1530636B1/en not_active Expired - Lifetime
- 2003-08-21 AT AT03792074T patent/ATE478142T1/de active
-
2005
- 2005-02-02 IL IL166657A patent/IL166657A/en not_active IP Right Cessation
- 2005-03-17 NO NO20051426A patent/NO333254B1/no not_active IP Right Cessation
-
2010
- 2010-11-19 CY CY20101101046T patent/CY1110936T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050058425A (ko) | 2005-06-16 |
| PT1530636E (pt) | 2010-11-17 |
| ATE478142T1 (de) | 2010-09-15 |
| SI1530636T1 (sl) | 2010-12-31 |
| EP1530636A1 (en) | 2005-05-18 |
| NO333254B1 (no) | 2013-04-22 |
| WO2004018675A1 (en) | 2004-03-04 |
| AU2003258425B2 (en) | 2008-02-14 |
| CY1110936T1 (el) | 2015-06-10 |
| DE60333839D1 (de) | 2010-09-30 |
| IL166657A0 (en) | 2006-01-15 |
| CA2494764A1 (en) | 2004-03-04 |
| NO20051426L (no) | 2005-05-12 |
| JP2006502243A (ja) | 2006-01-19 |
| US7285541B2 (en) | 2007-10-23 |
| JP4620585B2 (ja) | 2011-01-26 |
| EP1530636B1 (en) | 2010-08-18 |
| KR101052289B1 (ko) | 2011-07-27 |
| AU2003258425A1 (en) | 2004-03-11 |
| US20040082534A1 (en) | 2004-04-29 |
| IL166657A (en) | 2010-05-31 |
| NZ538288A (en) | 2008-04-30 |
| CA2494764C (en) | 2013-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110936T1 (el) | Θεραπεια μελανωματος με μειωση των επιπεδων της clusterin | |
| Lee et al. | Brazilin inhibits UVB-induced MMP-1/3 expressions and secretions by suppressing the NF-κB pathway in human dermal fibroblasts | |
| Jia et al. | (–)-Epigallocatechin-3-gallate protects human skin fibroblasts from ultraviolet a induced photoaging | |
| WO2007085018A3 (en) | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution | |
| EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
| PT1297851E (pt) | Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca | |
| Hwang et al. | A mechanism of low molecular weight fucoidans degraded by enzymatic and acidic hydrolysis for the prevention of UVB damage | |
| WO2000049937A3 (en) | Trpm-2 antisense therapy | |
| TW200609227A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
| EP4640281A3 (en) | Inhibition of metastasis by compounds which reduce the persistent part of the voltage-gated sodium channel | |
| EA200802223A1 (ru) | 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90 | |
| SE0301888D0 (sv) | New use VII | |
| DK1196414T3 (da) | Prolægemiddel af carbamathæmmer for IMPDH | |
| BR0011130A (pt) | Inibidores de metaloproteases | |
| EA200802329A1 (ru) | Производные триазола ii | |
| HN2000000040A (es) | Inhibidores de la sorbitol deshidrogenasa | |
| SE0301882D0 (sv) | New use I | |
| NO20033665D0 (no) | Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer | |
| BR0306643A (pt) | Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical | |
| AU2558300A (en) | Substituted stilbene compounds with vascular damaging activity | |
| AU2009246603A8 (en) | Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction | |
| Sheipouri et al. | RETRACTED: Characterisation of the Kynurenine Pathway in Skin‐Derived Fibroblasts and Keratinocytes | |
| MX339096B (es) | Compuestos inhibidores de metaloproteasa a base de feniletiniltiofeno y su uso en el tratamiento del dolor y otras enfermedades. | |
| NO20002218D0 (no) | Anvendelse av mirtazepin for behandling av søvnapne | |
| AU3934000A (en) | Inhibitors of endothelin-1 synthesis |